Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Gynecologic 2Endocrine 2Dermatologic 2Thoracic 1Sarcoma 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 551Lung Neoplasms 313Small Cell Lung Carcinoma 87Colorectal Neoplasms 71Melanoma 68Breast Neoplasms 60Neoplasms 55Ovarian Neoplasms 47Neoplasm Metastasis 45Carcinoma, Renal Cell 45Squamous Cell Carcinoma of Head and Neck 43Pancreatic Neoplasms 39Stomach Neoplasms 37Triple Negative Breast Neoplasms 31Head and Neck Neoplasms 30Esophageal Neoplasms 28Endometrial Neoplasms 25Prostatic Neoplasms 24Uterine Cervical Neoplasms 23Urinary Bladder Neoplasms 23Brain Neoplasms 22Colonic Neoplasms 21Mesothelioma 20Mesothelioma, Malignant 18Carcinoma, Hepatocellular 18Sarcoma 16Carcinoma, Transitional Cell 15Adenocarcinoma of Lung 15Lung Diseases 14NSCLC 13

Interventions

atezolizumab 1Immunoglobulin G 1Disulfides 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Adenocarcinoma, Mucinous × Thoracic × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡